A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Chronic Low Back Pain (CLBP), sponsored by Eli Lilly and Company. Active, not recruiting at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.
Among the 16 studies testing retatrutide in Obesity, this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 3, and was the 13th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Hudson Biotech · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, retatrutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 586 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 392 across the 16 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 33rd largest by planned enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 51 in phase 3, reaches primary completion later than 26 of the 54 other live ones, and was the 83rd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
4 of the studies testing retatrutide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
| NCT07035093Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | 2027-09 |
| NCT07467447Hudson BiotechEffect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | 2027-03-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing retatrutide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Retatrutide subcutaneously (SC)
Drug: Retatrutide
Participants will receive Placebo SC
Drug: Placebo
Administered SC
Also known as: LY3437943
Administered SC
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Time frame: Baseline, up to 72 weeks
Percent Change from Baseline in Body Weight
Time frame: Baseline, up to 72 weeks
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale
Time frame: Baseline, up to 72 weeks
Number of Participants with Reduction in Body Weight
Time frame: Baseline, up to 72 weeks
Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS)
Time frame: Baseline, up to 72 weeks
Change in Pain Interference as Measured by PROMIS
Time frame: Baseline, up to 72 weeks
Change in Sleep as Measured by PROMIS
Time frame: Baseline, up to 72 weeks
Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2)
Time frame: Baseline, up to 72 weeks
Change in Waist Circumference
Time frame: Baseline, up to 72 weeks
Change in Biomarkers of Inflammation as Measured by Blood Test
Time frame: Baseline, up to 72 weeks
Change in Blood Pressure
Time frame: Baseline, up to 72 weeks
Change in Glycemic Control
Time frame: Baseline, up to 72 weeks
Percent Change in Total Cholesterol
Time frame: Baseline, up to 72 weeks
Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)
Time frame: Baseline, up to 72 weeks
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 28 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retatrutide